非小细胞肺癌患者血清中MIF表达的临床意义

The expression and clinical significance of serum macrophage migration inhibitory factor in non-small-cell lung carcinoma

目的探讨非小细胞肺癌患者血清中巨噬细胞移动抑制因子(MIF)的表达水平及其临床意义。方法应用ELISA法测定60例非小细胞肺癌患者、50例良性肺部疾病患者和30例健康对照者血清中MIF水平,并进行比较分析。结果非小细胞肺癌组、良性肺部疾病组和健康对照组血清中MIF水平分别是23.2、13.0和7.5μg/L。非小细胞肺癌组MIF表达水平高于良性肺部疾病组和健康对照组(分别P<0.05,P<0.01)。血清MIF的水平与临床分期、肿瘤大小和是否转移有关(P<0.05)。结论血清MIF在非小细胞肺癌中高表达,并对临床分期、判断淋巴结转移及治疗指导具有重要临床意义。

Objective To investigate the expression of serum macrophage migration inhibitory factor（MIF） in non-small lung carcinoma and analyze the clinical significance. Method The expression of MIF was measured by ELISA in 30 health controls,50 benign lung disease patients and 60 non-small-cell lung carcinomachronic. Results The serum concentrations of MIF were significantly higher in non-small-cell lung carcinoma（23.2 μg/L） than that in benign lung disease and in health controls（13.0 μg/L,7.5 μg/L）（P〈0.05,P〈0.01,respectively）. MIF expression was positively correlated with clinical stage,tumor size and metastasis（P〈0.05）. Conclusion The serum level of MIF washigh in nonsmall-cell lung carcinoma and was helpful in the evaluation of lymph node metastasis,and TNM stagein cancer treatment.